ArticleAntimicrobial agents and chemotherapy2025
Functional and structural analyses of amino acid sequence variation in PDC β-lactamase reveal different mechanistic pathways toward cefiderocol resistance in
Abstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global trends in carbapenem-resistant gram-negative bacteria research (2020-2025): a bibliometric analysis and systematic review.Frontiers in cellular and infection microbiology · 2025Pooled it
- Article
- Article
- Mechanisms involved in cefiderocol resistance in FrenchAntimicrobial agents and chemotherapy · 2026Article
- Genetic and biochemical characterization of OXA-1054, a carbapenem-hydrolyzing class D β-lactamase conferring broad-spectrum β-lactam resistance inAntimicrobial agents and chemotherapy · 2026Article
- Ceftazidime-avibactam resistance evolution inAntimicrobial agents and chemotherapy · 2026Article
- Article
- In vivo evolution of resistance to novel β-lactam/β-lactamase inhibitor combinations through overproduction of the horizontally acquired extended-spectrum AmpC β-lactamase FOX-14 and porin disruption in Serratia marcescens.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Contribution of mutational resistance mechanisms and acquired β-lactamases to cefiderocol/xeruborbactam susceptibility inAntimicrobial agents and chemotherapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Lucía González-PintoServicio de Microbiología & Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0002-8387-3784
María Antonia Gomis-FontServicio de Microbiología & Instituto de Investigación Sanitaria Illes Balears (IdISBa), Hospital Universitario Son Espases, Palma de Mallorca, Spain.ORCID 0000-0001-6042-5674
Emilio LenceCentro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.ORCID 0000-0001-9489-9421
Michelle Outeda-GarcíaServicio de Microbiología & Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0002-6737-0239
Tania Blanco-MartínServicio de Microbiología & Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0009-0003-1636-6429
Salud Rodríguez-PallaresServicio de Microbiología & Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0002-8270-0259
Lucía Sánchez-PeñaServicio de Microbiología & Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0009-0007-5696-5812
Isaac Alonso-GarcíaServicio de Microbiología & Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0002-1681-969X
Juan Carlos Vázquez-UchaServicio de Microbiología & Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0003-4949-0779
Alejandro BeceiroServicio de Microbiología & Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0002-6340-7815
Germán BouServicio de Microbiología & Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0001-8837-0062
Concepción González-BelloCentro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.ORCID 0000-0001-6439-553X
Antonio Oliver *Servicio de Microbiología & Instituto de Investigación Sanitaria Illes Balears (IdISBa), Hospital Universitario Son Espases, Palma de Mallorca, Spain.ORCID 0000-0001-9327-1894
Jorge Arca-Suárez *Servicio de Microbiología & Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.ORCID 0000-0002-4248-503X
Funding
Axencia Galega de Innovacion (GAIN) - Xunta de Galicia ED431C 2021/29Axencia Galega de Innovacion (GAIN) - Xunta de Galicia IN606A 2023/023Axencia Galega de Innovacion (GAIN) - Xunta de Galicia IN606A 2024/022Axencia Galega de Innovacion (GAIN) - Xunta de Galicia IN606B 2022/009Axencia Galega de Innovacion (GAIN) - Xunta de Galicia IN607A 2016/22Axencia Galega de Innovacion (GAIN) - Xunta de Galicia IN607D 2021/12Axencia Galega de Innovacion (GAIN) - Xunta de Galicia IN607D 2024/008Axencia Galega de Innovacion (GAIN) - Xunta de Galicia - Centro Singular de Investigacion de Galicia accreditation 2024-2027 ED431G 2023/03Centro de Investigacion Biomedica en Red de Enfermedades Infecciosas (CIBERINFEC) CB21/13/00055Centro de Investigacion Biomedica en Red de Enfermedades Infecciosas (CIBERINFEC) CB21/13/00099Instituto de Salud Carlos III CM23/00095Instituto de Salud Carlos III CM23/00104Instituto de Salud Carlos III FI22/00039Instituto de Salud Carlos III FI23/00074Instituto de Salud Carlos III JR21/00026Instituto de Salud Carlos III JR23/00036Instituto de Salud Carlos III PI20/01212,PI23/00851Instituto de Salud Carlos III PI22/01212Spanish State Agency of Research PID2022-136963OB-I00/AEI/10.13039/501100011033
Abstract
A wide variety of clinically observed amino acid alterations in the
Indexed as
Anti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCephalosporinaseCephalosporinsPseudomonas aeruginosaAmino Acid SequenceCefepimeCefiderocolCeftazidimeHydrolysisKineticsMicrobial Sensitivity TestsMolecular Dynamics SimulationTazobactamAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCefepimeCefiderocolCeftazidimeCephalosporinaseCephalosporinsTazobactamAmpC β-lactamasecefiderocolPseudomonas aeruginosaβ-lactam resistance
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.